Aims: Steviol glycosides are the sweet components extracted from medicinal plant Stevia rebaudiana Bertoni, which have antihyperglycaemic effects. Steviol glucuronide (SVG) is the metabolite excreted in human urine after oral administration of steviol glycosides. We aimed to clarify whether SVG exerts direct insulin stimulation from pancreatic islets and to explore its mode of action. Results: SVG dose-dependently increased insulin secretion from mouse islets with 10 −7 mol/L exerting the maximum effect in the presence of 16.7 mmol/L glucose (P < .001). The insulinotropic effect of SVG was critically dependent on the prevailing glucose concentration, and SVG (10 −7 mol/L) enhanced insulin secretion at or above 11.1 mmol/L glucose (P < .001) and showed no effect at lower glucose concentrations. During perifusion of islets, SVG (10 −7 mol/L) had a long-acting and apparently reversible insulinotropic effect in the presence of 16.7 mmol/L glucose (P < .05).
| INTRODUC TI ON
Steviol glycosides are a group of sweet diterpene glycosides found in the leaves of Stevia rebaudiana Bertoni, a scrub plant native to the subtropical regions of South America. To date, more than 40 steviol glycosides have been identified from stevia leaf extracts, of which stevioside and rebaudioside A are the most abundant. 1, 2 Highly purified steviol glycosides have been permitted for use as food sweetener in numerous countries and regions, including Japan, the European Union and the United States. Besides the sweet property, steviol glycosides also possess potential therapeutic benefits. A multitude of preclinical and clinical studies have demonstrated their antihyperglycaemic effects, including lowering postprandial blood glucose, 3, 4 enhancing insulin secretion [5] [6] [7] [8] [9] [10] [11] and improving insulin sensitivity.
12,13
Steviol glycosides share steviol (ent-13-hydroxykaur-16-en-18-oic acid) as the aglycone core structure and only differ in the number and type of sugar molecules attached (at R1 and R2), see Figure 1A Moreover, all steviol glycosides found in stevia leaf extracts share the same metabolic pathway. 2, 14 As previously unanimously described, 1, [14] [15] [16] enzymes and acid present in the upper gastrointestinal tract are not able to hydrolyse the glycosidic bonds in steviol glycosides. However, the colonic microflora is able to degrade steviol glycosides to steviol. Most of the steviol is absorbed quickly from the intestine and transported to the liver; the rest is excreted in the faeces. In the liver, steviol is conjugated with glucuronic acid to form SVG ( Figure 1B ), which is excreted in the urine in humans and in faeces in rats. The difference in excretion between species is due to the lower molecular weight threshold for biliary excretion in rats than in humans. 17 Steviol glycoside derivatives do not accumulate in the body. Minor differences in the metabolism of steviol glycosides exist. 1 Intake of rebaudioside A results in slightly lower SVG concentrations (59%) than following stevioside (62%) consumption.
18
After oral administration of steviol glycosides in humans, SVG is the main metabolite (no free steviol can be detected) in plasma and no other derivatives could be found except SVG in the urine.
19
Hence, it is highly relevant to investigate whether SVG is the active metabolite after oral administration of steviol glycosides.
Unfortunately, there is no research available on the bioactive properties of SVG concerning insulin secretory capacity. We hypothesize that SVG has insulinotropic effects. The purpose of the present in vitro experiments was to clarify whether SVG stimulates insulin secretion from normal mouse islets of Langerhans and to test the transcription of key insulin regulatory genes to reveal the mode of action.
| MATERIAL S AND ME THODS

| Purification of SVG
SVG was purified from human urine as previously described. 19, 20 In brief, stevioside (250-mg capsules) was given thrice daily for 3 days to 10 healthy volunteers; thereafter, a 24-hour urine sample was collected, between 1124 and 2494 mL from each volunteer.
Total urine fraction was applied for column chromatography with an Amberlite XAD-2 column (Sigma). The column bed volume was 200 mL, being sufficient for the adsorption of amphipathic molecules of a 24-hour urine. About 600 mg of urine residue isolated from the prior purification step was dissolved in MeOH and ad- were added. After enzymatic reaction, the reaction mixture was freeze-dried followed by derivatization reaction with 4-(bromomethyl)-7-methocoumarin. All fractions containing enzyme-sensitive steviol conjugates eluted as a single large peak from the silica gel column, indicating the presence of only one steviol conjugate in the urine samples. All fractions containing this steviol conjugate were pooled, and the solvent was evaporated. The residue was subjected to preparative TLC, and around 10 mg purified, white crystalline SVG was obtained. 
| Isolation of islets
| Static incubation and perifusion of islets
After overnight culture, the NMRI female mice islets were rinsed twice with a modified Krebs-Ringer bicarbonate buffer, supple- In the perifusion experiment, 30 pre-incubated (room temperature) islets were transferred to each of the chambers of the perifusion system (Suprafusion 2 500, Brandel). 22 The experiments were 
| Insulin assay
Insulin was analysed by radioimmunoassay using a guinea pig antiporcine insulin antibody, mono-125 I-(Tyr A14)-labelled human insulin as tracer and rat insulin as standard (all from Novo Nordisk). The separation of bound and free radioactivity was performed using ethanol, and the inter-and intra-assay variation coefficients were both <5%.
| Purification of RNA
After overnight incubation (37°C), mouse pancreatic islets were incubated (37°C) for 72 hours in RPMI 1640 with 11.1 mmol/L glucose in the presence or absence of 10 −7 mol/L SVG. Thereafter, 100-120 islets for each sample were pooled in 1 mL of Trizol reagent (Ambion, Life Technologies) before RNA purification. Total RNA was isolated according to local laboratory protocol. RNA quality was analysed on a NanoDrop 8000 Spectrophotometer (Thermo Fisher Scientific).
The concentration of RNA was normalized to 50 ng/μL, and all samples were kept at −80°C until cDNA reaction. 
| Quantitative real-time RT-PCR
| Statistical analysis
All data analysis was performed with GraphPad Prism Software Figure 3 , SVG potentiated insulin secretion at glucose levels of 11.1 mmol/L and higher (P < .001), whereas no effect was detected at 3.3 or 6.6 mmol/L glucose.
| Effects of SVG on dynamic insulin release from perifused mouse islets
In the presence of 3.3 mmol/L glucose, the addition of SVG did not change basal insulin secretion from perifused islets. As expected, the increase in glucose level from 3. Table 2 .
| Effects of 72-h exposure to SVG on gene transcription in mouse islets
To gain further insight into the effects of SVG on insulin secretion, transcript levels of a number of selected genes were examined in mouse islets ( Figure 5 ). After 72 hours of intervention, SVG (10 −7 mol/L) significantly decreased transcript level of beta-2-microglobulin (B2m, P < .05, Figure 5N) and significantly increased transcript level of glucagon receptor by 102% (Gcgr, P = .05, Figure 5M ). Moreover, SVG (10 −7 mol/L) markedly upregulated transcript level of pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1, P = .06, Figure 5E ), nearly reached a significant level. As depicted at Figure 5F , 5I, 5J, 5P and 5Q, islets from the SVG group enhanced transcript levels of NK2 homeobox 2 (Nkx2-2, 164%, P = .12), pancreatic and duodenal homeobox 1 (Pdx1, 45%, P = .21), NK6 homeobox 1 (Nkx6.1, 59%, P = .21), thymoma viral proto-oncogene 1 (Akt1, 40%, P = .2) and insulin receptor (Insr, 25%, P = .18) compared with islets from the control group. 
TA B L E 1 List of genes investigated for transcription from mouse pancreatic islets with TaqMan assay ID
| D ISCUSS I ON
Type 2 diabetes (T2D) is a metabolic disease characterized by persistent hyperglycaemia secondary to inadequate insulin secretion, insulin resistance, excessive glucagon secretion and/or a combination.
The epidemic increase in the prevalence of T2D is most pronounced in lower-income countries. 24 Due to the high price of the newer antidiabetic drugs as well as the risk of severe side effects of some of the current T2D therapies, it is important to continue the search of more effective, safer and cost-effective antidiabetic agents. Hundreds of 
25-27
As mentioned, the effective compounds extracted from stevia, steviol glycosides, are acknowledged to have antihyperglycaemic effects. Our group previously demonstrated that stevioside reduces postprandial blood glucose levels in type 2 diabetic subjects, 4 and suppresses glucose response to a glucose tolerance test, increases insulin secretion, reduces glucagon release and lowers blood pressure in type 2 diabetic Goto-Kakizaki rats. 7, 11 It is important to stress that stevioside is unlikely to increase the risk of hypoglycaemia, since
insulin stimulation disappeared at normal or low circulating glucose concentrations. When supplemented to soy-based diet, stevioside
shows beneficial effects on the development of the metabolic syndrome with hyperglycaemia, hypertension and dyslipidaemia.
10,28
Furthermore, we have disclosed that stevioside, rebaudioside A, steviol (steviol glycosides' aglucon) and isosteviol (steviol glycosides' derivative) have the capability to enhance insulin secretion from isolated mouse islets in a dose-and glucose-dependent manner. 8, 9, 13, 23 In the present study, we have found that the metabolite, SVG, possesses the same properties. In static incubation studies, the insulinotropic effect of SVG was present in a broad concentration range, with the maximal effect at 10 −7 mol/L. Despite the potent insulin release at glucose concentrations 11.1 and 16.7 mmol/L, it is important to note that no insulinotropic action of SVG was present at lower glucose levels of 3.3 and 6.6 mmol/L. This may indicate that the risk of hypoglycaemia in vivo is eliminated.
In perifusion experiments, we applied the maximal effective con- These results emphasize that steviol glycosides have a promising potential in the treatment of T2D, since the insulinotropic action of their metabolic end product, SVG, only operates at high glucose level, but disappears at low glucose concentration, which is indicative of improved glycaemic control with a good safety profile. 29 The risk of hypoglycaemia in T2D patients treated with antidiabetic medications, such as sulfonylureas, is a major safety issue that can be fatal.
30
In addition to imposing a risk of hypoglycaemia, long-term use of oral hypoglycaemic agents induces desensitization to metabolic stimuli in patients with T2D. 31 In mice, stevioside has been shown to counteract the suppressed glucose-stimulated insulin induced by the sulfonylurea, glyburide. TA B L E 2 Average insulin AUC (ng*min/ mL) from control and intervention group at different time intervals from the perifusion study on steviol glucuronide F I G U R E 5 Effects of 72-h incubation (37°C) at 11.1 mmol/L glucose with or without 10 −7 mol/L steviol glucuronide on isolated mouse islets gene transcription. Transcript abundance of 17 specific genes was studied by real-time RT-PCR using TaqMan assays. Seven samples were obtained in each treatment, and the samples were measured in quadruplicates. Data are presented as mean ± SEM. *P ≤ .05
(N) * histocompatibility (MHC) class I molecule has been found to be positively correlated with diabetes duration. 33 In addition, Pavlovic et al found elevated glucose levels to increase MHC class I mRNA levels twofold in both rat and human islet cell preparations, suggesting that a hyperglycaemic state is able to increase expression in islet β-cells. 34 Javadi et al reported a significant increase in B2m in STZ-induced diabetic rabbits. Following STZ injection, serum glucose level gradually increased, while the B2m level rose rapidly two days after injection. 35 In this light, it is interesting that SVG has the ability to downregulate the gene transcription of B2m and may thereby potentially decrease the incidences of microvascular and macrovascular complications such as atherosclerosis in untreated T2D subjects.
Glucagon is secreted from pancreatic α-cells that, as a major counterregulatory hormone to insulin, is essential for maintaining Upregulation of these genes indicates enhanced insulin release.
| CON CLUS ION
To our knowledge, this is the first demonstration of a direct effect of SVG on insulin secretion. Our hypothesis was confirmed in the present study that SVG is insulinotropic. SVG dose-and glucose-dependently potentiates insulin release from isolated mouse islets and 
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